MICHAEL TAWIAH: Open Payments
NPI 1932671575 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,805 in 111 payments from 20 companies in 2025. Trend: 2023 $1,608 · 2024 $1,709 · 2025 $2,805
Food & beverage: $2,805
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 14 | $403 |
| Madrigal Pharmaceuticals | 17 | $363 |
| ABBVIE INC. | 15 | $344 |
| Aimmune Therapeutics, Inc. | 9 | $265 |
| QOL Medical, LLC | 6 | $227 |
| Ipsen Biopharmaceuticals, Inc | 4 | $215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $210 |
| Lilly USA, LLC | 7 | $150 |
| PFIZER INC. | 9 | $142 |
| Phathom Pharmaceuticals, Inc. | 4 | $109 |
Products named: TREMFYA, REZDIFFRA, ZENPEP, Sucraid, IQIRVO, ENTYVIO, LINZESS, XELJANZ.
Industry payments across CT — which companies pay providers there.
